Detailed description page of SalivaDB

This page displays user query in tabular form.

SAL_24649 details
Primary information
SALIDSAL_24649
Biomarker namehsa-miR-124-3p
Biomarker TypeDiagnostic
Sampling MethodAll 216 individuals belong to the high altitude mestizo Ecuadorian population (2,800 meters above sea level). Unstimulated whole mouth resting saliva was collected from 108 HNSCC patients (stages 1 to 4)
Collection MethodTotal RNA from 200 mL of saliva of 10 healthy controls and 10 patients was extracted using TRIzolns were measured using a NanoDrop 2000 (ThermoScientific, Waltham, MA, USA).
Analysis MethodqRT-PCR
Collection SiteSaliva
Disease CategoryCancer
Disease/ConditionHead and Neck Cancer
Disease SubtypeHead and Neck Squamous Cell Carcinoma (HNSCC)
Fold Change/ Concentration3.2
Up/DownregulatedUpregulated
ExosomalNA
OrganismHomo sapiens
PMID30584540
Year of Publication2018
Biomarker IDhsa-miR-124-3p
Biomarker CategorymiRNA
SequenceUAAGGCACGCGGUGAAUGCCAA
Title of studySalivary MicroRNAs for Early Detection of Head and Neck Squamous Cell Carcinoma: A Case-Control Study in the High Altitude Mestizo Ecuadorian Population
Abstract of studyHead and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer with the highest incidence worldwide. HNSCC is often diagnosed at advanced stages, incurring significant high mortality and morbidity. The use of saliva, as a noninvasive tool for the diagnosis of cancer, has recently increased. Salivary microRNAs (miRNAs) have emerged as a promising molecular tool for early diagnosis of HNSCC. The aim was to identify the differential expression of salivary miRNAs associated with HNSCC in the high altitude mestizo Ecuadorian population. Using PCR Arrays, miR-122-5p, miR-92a-3p, miR-124-3p, miR-205-5p, and miR-146a-5p were found as the most representative ones. Subsequently, miRNAs expression was confirmed in saliva samples from 108 cases and 108 controls. miR-122-5p, miR-92a-3p, miR-124-3p, and miR-146a-5p showed significant statistical difference between cases and controls with areas under the curve (AUC) of 0.73 (p < 0.001), 0.70 (p < 0.001), 0.71 (p = 0.002), and 0.66 (p = 0.008), respectively. miRNAs were also deregulated in between HNSCC localizations. A differentiated expression of miR-122-5p between oral cancer and oropharynx cancer (AUC of 0.96 p = 0.01) was found: miR-124-3p between larynx and pharynx (AUC = 0.97, p < 0.01) and miR-146a-5p between larynx, oropharynx, and oral cavity (AUC = 0.96, p = 0.01). Moreover, miR-122-5p, miR-124-3p, miR-205-5p, and miR-146a-5p could differentiate between HPV+ and HPV- (p=0.004). Finally, the expression profiles of the five miRNAs were evaluated to discriminate HNSCC patient's tumor stages (TNM 2-4). miR-122-5p differentiates TNM 2 and 3 (p = 0.002, AUC = 0.92), miR-124-3p TNM 2, 3, and 4 (p < 0.001, AUC = 98), miR-146a-5p TNM 2 and 3 (p < 0.001, AUC = 0.97), and miR-92a-3p TNM 3 (p < 0.001, AUC = 0.99). Taken together, these findings show that altered expression of miRNAs could be used as biomarkers for HNSCC diagnosis in the high altitude mestizo Ecuadorian population.